|
US9096537B1
|
|
Compositions and methods for the treatment of mucositis
|
|
US9206111B1
|
|
Compositions and methods for the treatment of neurological diseases
|
|
US9173877B1
|
|
Compositions and methods for the treatment of local pain
|
|
US2016122313A1
|
|
Compositions and methods for the treatment of diabetes
|
|
US2016122293A1
|
|
Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
|
|
US2016120838A1
|
|
Compositions and methods for the treatment of inflammatory bowel disease
|
|
US2016122282A1
|
|
Compositions and methods for the treatment of neurological disorders
|
|
US9150557B1
|
|
Compositions and methods for the treatment of hyperglycemia
|
|
US9290486B1
|
|
Compositions and methods for the treatment of epilepsy
|
|
US9108942B1
|
|
Compositions and methods for the treatment of moderate to severe pain
|
|
US9175008B1
|
|
Prodrugs of anti-platelet agents
|
|
US9321716B1
|
|
Compositions and methods for the treatment of metabolic syndrome
|
|
US9284287B1
|
|
Compositions and methods for the suppression of carbonic anhydrase activity
|
|
WO2015033279A1
|
|
Compositions and methods for the treatment of homocystinuria
|
|
WO2015028976A2
|
|
Compounds and methods for the treatment of inflammatory diseases
|
|
WO2015028957A2
|
|
Compounds and methods for the treatment of respiratory diseases
|
|
WO2015028956A1
|
|
Compositions and methods for the treatment of fatty acid oxidation disorders
|
|
WO2015028928A2
|
|
Compositions and methods for the treatment of inflammation and arthritis
|
|
WO2015028927A1
|
|
Compositions and methods for the treatment of metabolic diseases
|
|
WO2015022613A1
|
|
Compositions and methods for the treatment of diabetes and pre-diabetes
|
